These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19911992)

  • 21. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir.
    Ren H; Wang G; Wang S; Chen H; Chen Z; Hu H; Cheng G; Zhou P
    MAbs; 2016; 8(6):1156-66. PubMed ID: 27167234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.
    Gray SA; Moore M; VandenEkart EJ; Roque RP; Bowen RA; Van Hoeven N; Wiley SR; Clegg CH
    Antiviral Res; 2016 Jul; 131():100-8. PubMed ID: 27109194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
    Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
    J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
    Smee DF; Barnard DL; Jones SM
    Antiviral Res; 2016 Dec; 136():45-50. PubMed ID: 27771390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
    Pizzorno A; Abed Y; Rhéaume C; Boivin G
    Antiviral Res; 2014 May; 105():54-8. PubMed ID: 24583158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.
    Prabakaran M; Prabhu N; He F; Hongliang Q; Ho HT; Qiang J; Meng T; Goutama M; Kwang J
    PLoS One; 2009 May; 4(5):e5672. PubMed ID: 19478856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
    Govorkova EA; Ilyushina NA; Boltz DA; Douglas A; Yilmaz N; Webster RG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1414-24. PubMed ID: 17296744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
    Herbreteau CH; Denizot M; Lowther S; Riddell S; Frazer L; Haining J; Arkinstall R; Payne J; Harper J; Johnson D; Pasquier A; Middleton D; Saluzzo JF
    Immunotherapy; 2016 Sep; 8(9):1021-32. PubMed ID: 27380317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
    Masihi KN; Schweiger B; Finsterbusch T; Hengel H
    J Chemother; 2007 Jun; 19(3):295-303. PubMed ID: 17594925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
    Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
    Smee DF; Wong MH; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2006; 17(4):185-92. PubMed ID: 17066897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.
    Simmons CP; Bernasconi NL; Suguitan AL; Mills K; Ward JM; Chau NV; Hien TT; Sallusto F; Ha do Q; Farrar J; de Jong MD; Lanzavecchia A; Subbarao K
    PLoS Med; 2007 May; 4(5):e178. PubMed ID: 17535101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
    Takahashi E; Sawabuchi T; Kimoto T; Sakai S; Kido H
    J Dairy Sci; 2019 Nov; 102(11):9559-9569. PubMed ID: 31495632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
    Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
    Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice.
    Barnard DL; Wong MH; Bailey K; Day CW; Sidwell RW; Hickok SS; Hall TJ
    Antivir Chem Chemother; 2007; 18(3):125-32. PubMed ID: 17626596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.